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Minna Piipponen1,2, Liisa Nissinen1,2, Mehdi Farshchian1,2, Pilvi Riihila¨1,2, Atte Kivisaari1,2,
Markku Kallajoki3, Juha Peltonen4, Sirkku Peltonen1 and Veli-Matti Ka¨ha¨ri1,2Keratinocyte-derived cutaneous squamous cell carcinoma (cSCC) is the most common metastatic skin cancer,
and its incidence is increasing globally. Long noncoding RNAs (lncRNA) are involved in various biological
processes, and their role in cancer progression is emerging. Whole transcriptome analysis of cSCC cells (n ¼ 8)
and normal human epidermal keratinocytes (n ¼ 4) revealed overexpression of long intergenic ncRNA
(LINC00162) in cSCC cells. The expression of LINC00162 in cSCC cells was upregulated by inhibition of the p38a
and p38d mitogen-activated protein kinases. Analysis of tissue sections by RNA in situ hybridization showed
that LINC00162 is specifically expressed by tumor cells in cSCCs but not by keratinocytes in normal skin in vivo.
Knockdown of LINC00162 inhibited proliferation and migration of cSCC cells, and suppressed the growth
of human cSCC xenografts in vivo. Furthermore, knockdown of LINC00162 inhibited extracellular signal-
regulated kinase 1/2 activity and upregulated expression of dual specificity phosphatase 6 (DUSP6) in cSCC
cells. Based on these observations, LINC00162 was named p38 inhibited cutaneous squamous cell carcinoma
associated lincRNA (PICSAR). Our results provide mechanistic evidence for the role of PICSAR in promoting
cSCC progression via activation of extracellular signal-regulated kinase 1/2 signaling pathway by down-
regulating DUSP6 expression. These results also identify PICSAR as a biomarker and putative therapeutic target
in cSCC.
Journal of Investigative Dermatology (2016) 136, 1701e1710; doi:10.1016/j.jid.2016.03.028INTRODUCTION
Epidermal keratinocyte-derived cutaneous squamous cell
carcinoma (cSCC) is the most commonmetastatic skin cancer,
the incidence of which is increasing worldwide (Madan et al.,
2010; Ratushny et al., 2012). Solar UV radiation, chronic
ulcers, and immunosuppression have been recognized as
important risk factors for cSCC (Kivisaari and Ka¨ha¨ri, 2013).
Primary cSCCs harbor a tendency for recurrence and metas-
tasis, and the prognosis of metastatic cSCCs remains unfa-
vorable in the absence of targeted therapies (Czarnecki et al.,
2002). An important event in keratinocyte carcinogenesis is
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article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bywhich is followed by marked accumulation of UV-induced
simple mutations (Durinck et al., 2011). Another early event
in the development of cSCC is loss-of-function mutation of
NOTCH1 (South et al., 2014; Wang et al., 2011). Tran-
scription of NOTCH1 is regulated by p53, and inactivation
of p53 can lead to downregulation of NOTCH1 expression
(Lefort et al., 2007). Mutations in HRAS, KRAS, and EGFR
have also been detected in cSCC, emphasizing the role of
EGFR and extracellular signal-regulated kinase 1/2 (ERK1/2)
signaling in development of cSCC (Ratushny et al., 2012).
Recently, previously unreported markers for progression of
cSCC have been identified and characterized (Farshchian
et al., 2011, 2015; Liu et al., 2013; Riihila¨ et al., 2014,
2015; Trimmer et al., 2012), but understanding of the
molecular basis of cSCC progression from premalignant
lesion (actinic keratosis, AK) to cSCC in situ (cSCCIS) and
eventually to invasive cSCC remains incomplete.
Advances in whole genome sequencing have revealed that
human genome is extensively transcribed into RNA, but only
a fraction of the RNA transcripts encode proteins (Djebali
et al., 2012). The sequence of protein coding genes
comprise approximately 2% of the human genome and the
majority of the remaining genomic sequences are transcribed
into a wide range of noncoding RNAs, including microRNAs,
small nucleolar RNAs, piwi-interacting RNAs, and long
noncoding RNAs (lncRNAs) (International Human Genome
Sequencing Consortium, 2004). LncRNAs are a diverse and
largely uncharacterized group of noncoding transcripts.
Currently, more than 18,000 annotated lncRNA transcripts
have been identified in the human genome and they areestigative Dermatology. This is an open access
-nc-nd/4.0/). www.jidonline.org 1701
Figure 1. Expression of PICSAR is specifically upregulated in cutaneous squamous cell carcinoma (cSCC) cells. (a) The heatmap of whole transcriptome
analysis (SOLiD) showing significantly (P < 0.05) regulated lncRNAs in primary (Prim; n ¼ 5) and metastatic (Met; n ¼ 3) cSCC cell lines and in normal human
epidermal keratinocytes (NHEK) (n ¼ 4). LncRNA genes were identified based on the catalogue of annotated lncRNAs by The Human Genome Organization
Gene Nomenclature Committee. Statistical analysis was performed with the Mann-Whitney U-test. (b) Expression of PICSAR in the same cSCC cell lines and in
NHEKs (n ¼ 8) was determined by qRT-PCR. b-Actin was used as a reference gene. (c) Expression of PICSAR in cSCC in vivo (n ¼ 6) and normal skin (n ¼ 7) was
determined by qRT-PCR. b-Actin was used as a reference gene. (d) Expression of PICSAR in cSCC (UT-SCC12A) and NHEKs (NHEK78) was determined by RNA
in situ hybridization (RNA-ISH) and visualized by fluorescence microscopy. Scale bar ¼ 10 mm. (e) Left panel: expression PICSAR (red arrows) and matrix
metalloproteinase-13 (MMP-13) (blue arrows) in xenograft tumors established in SCID mice with human UT-SCC12A cells was determined with RNA-ISH and
visualized with two chromogens. Right panel: the fluorescence signal for PICSAR corresponds to the red chromogenic signal of the alkaline phosphatase (red
arrow) in the same TYPE 6 probe set used for PICSAR in the left panel. Scale bar ¼ 25 mm. PICSAR, P38 Inhibited Cutaneous Squamous cell carcinoma
Associated lincRNA; qRT-PCR, quantitative real-time reverse transcriptase-PCR; SCID, severe combined immunodeficient.
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intronic lncRNAs, or natural antisense transcripts (Bhartiya
et al., 2013; Moran et al., 2012). LncRNAs can function in
cell regulation in several ways. They can modulate gene
expression by regulating binding and activity of transcription
factors, and they can regulate mRNA stability directly or by
interacting with microRNAs (Geisler and Coller, 2013; Moran
et al., 2012; Rinn and Chang, 2012). Recent observations
have emphasized the role of lncRNAs in cancer progression,
suggesting them as important biomarkers and therapeutic
targets in different malignant tumors (Serviss et al., 2014;
Wahlestedt, 2013; Yang et al., 2014).
In this study, we have identified a previously uncharac-
terized lincRNA, LINC00162, which is specifically overex-
pressed by cSCC cells in culture and in vivo. The expression
of LINC00162 in cSCC cells was upregulated by inhibition of
p38a and p38d mitogen-activated protein kinases (MAPKs).
Knockdown of LINC00162 inhibited ERK1/2 activity and
proliferation and migration of cSCC cells, and markedly
suppressed the growth of human cSCC xenograft tumors
in vivo. On the basis of these observations and with the
permission of Human Genome Organization Gene Nomen-
clature Committee, we have named this lincRNA P38
Inhibited Cutaneous Squamous cell carcinoma Associated
lincRNA (PICSAR). These results indicate the oncogenic role
for this lincRNA and identify PICSAR as a biomarker forJournal of Investigative Dermatology (2016), Volume 136progression of cSCC and a potential therapeutic target in this
malignant tumor of skin.
RESULTS
Expression of PICSAR is specifically upregulated in
cSCC cells
The whole transcriptome analysis of cSCC cell lines (n ¼ 8)
and normal human epidermal keratinocytes (NHEKs; n ¼ 4)
was performed with RNA-seq and lncRNA genes were iden-
tified based on the catalogue of annotated lncRNAs by The
Human Genome Organization Gene Nomenclature Com-
mittee. The gene expression analysis revealed differential
expression of several lncRNAs in cSCC cells compared with
NHEKs (Figure 1a, Supplementary Figure S1 online). Among
these, PICSAR (LINC00162) was the most upregulated
lncRNA in cSCC cells compared with NHEKs (Figure 1a).
Analysis with quantitative real-time reverse transcriptase-PCR
(qRT-PCR) verified overexpression of PICSAR in cSCC cells
lines (n ¼ 8) and in cSCC tissues in vivo (n ¼ 6), whereas the
expression in NHEKs (n¼ 8) and normal skin (n¼ 7) was very
low (Figure 1b and c). The analysis of PICSAR expression with
RNA in situ hybridization (RNA-ISH) revealed specific mainly
cytoplasmic signal for PICSAR in cSCC cells but not in NHEKs
in culture (Figure 1d, Supplementary Figure S2 online).
Furthermore, analysis of tissue sections of xenografts estab-
lished with human cSCC cells (UT-SCC12A) with RNA-ISH
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(Figure 1e). Expression of matrix metalloproteinase-13 mRNA
was detected in cSCC cells in the same xenografts as a positive
control (Airola et al., 1997; Stokes et al., 2010).
PICSAR is expressed by cSCC tumor cells in vivo
To study the expression of PICSAR during cSCC progression
in vivo, tissue microarrays consisting of tissue samples
representing different stages of epidermal carcinogenesis,
that is, normal skin (n ¼ 9), UV-induced premalignant lesions
(AK; n ¼ 26), cSCCIS (n ¼ 20), and invasive cSCCs (n ¼ 21)
were analyzed using RNA-ISH. Expression of PICSAR was
detected in tumor cells in AK, cSCCIS, and cSCC, whereas no
signal was detected in normal skin (Figure 2aed). Analysis of
the PICSAR positive tissue sections revealed that the number
of positive sections increased with the progression from AK
(23%) to cSCCIS (35%) and cSCC (43%), whereas all sections
of normal skin were negative (Figure 2e).
Expressionof PICSAR is downregulatedbyp38MAPKpathway
Previous studies have demonstrated basal activation of ERK1/2
and p38 MAPKs in cSCC cells in culture and in vivo (Junttila
et al., 2007; Kivisaari et al., 2010; Toriseva et al., 2012). To
examine the regulation of basal PICSAR expression by ERK1/2
and p38 pathways, cSCC cells were treated for 24 hours
with MAPK/ERK kinase 1/2 (MEK1/2) inhibitor (PD98059) and
p38 inhibitors specific for p38a/b (SB203580) or all p38
isoforms (p38a/b/g/d) (BIRB796). Treatment of cSCC cells
with BIRB796 significantly upregulated PICSAR expression,
whereas treatment with PD98059 or SB203580 had no effect
(Figure 3a). To verify the regulation of PICSAR by p38a and
p38d, cSCC cells were transfected with p38a and p38d tar-
geted siRNAs alone and in combination. Consistent with the
results obtained with the chemical p38 inhibitors, knockdown
of p38d alone and in combination with p38a resulted in sig-
nificant upregulation of PICSAR in cSCC cells (Figure 3b). In
addition, adenoviral delivery of dominant negative mutant of
MAP kinase kinase 3b (MKK3b) (RAdMKK3bA; Wang et al.,
1998), the upstream activator of p38a and p38d resulted in
elevated expression of PICSAR (Figure 3c).
Knockdown of PICSAR inhibits proliferation and migration
of cSCC cells
To study the cellular functions of PICSAR, cSCC cells were
transfected with two PICSAR targeted siRNAs and control
siRNA and harvested 3 days after transfection. Effective
knockdown of PICSAR expression in cSCC cells was detected
using RNA-ISH (Figure 4a, lower panel; Supplementary Figure
S3 online). Analysis with qRT-PCR indicated that PICSAR
expression was decreased by 95e97% with siRNA1 and by
74e91%with siRNA2 (Figure 4a, upper panel; Supplementary
Figure S4a online), as compared with control siRNA trans-
fected cultures. Analysis of cell proliferation revealed that the
number of viable cSCC cells was significantly diminished after
PICSAR knockdowncomparedwith control siRNA-transfected
cultures using two different cSCC cell lines (Figure 4b,
Supplementary Figure S4b). Analysis of the corresponding cell
lysates showed that PICSAR knockdown resulted in a marked
decrease in the levels of p-ERK1/2 and marker of proliferation
Ki-67 (Figure 4c, Supplementary Figure S4c). In contrast,
knockdown of PICSAR had no effect on the activity of p38,c-Jun N-terminal kinase (JNK), or acutely transforming retro-
virus AKT8 in rodent T-cell lymphoma (Akt) (data not shown).
Analysis of cell migration after knockdown of PICSAR
expression was performedwith two different PICSAR targeting
siRNAs with two cSCC cell lines. The wound healing assay
showed that knockdown of PICSAR decreased cell migration
significantly in comparison with the control siRNA transfected
cells (Figure 4d and e, Supplementary Figure S4d and e).
Alteration of gene expression profile of cSCC cells after
PICSAR knockdown
To elucidate the molecular mechanisms of the effects of
PICSAR on cSCC cells, expression profiling of cSCC cells
(UT-SCC12A, UT-SCC59A, and UT-SCC118) transfected
with PICSAR siRNA1 and control siRNA was performed with
RNA-seq. Ingenuity pathway analysis of the RNA-seq
expression data showed a significant (P < 0.05; fold
change [FC] log2 > 0.5) decrease in biofunctions M-phase of
tumor cell lines, transformation of tumor cell lines, and
phosphorylation of L-serine (Figure 5a, upper panel). In
addition, canonical pathway ERK/MAPK signaling was
significantly regulated (P < 0.0001) in PICSAR knockdown
cSCC cells (Supplementary Figure S5 online).
Differentially expressed genes in PICSAR knockdown cSCC
cells were also significantly associated with specific gene
ontology terms and Kyoto Encyclopedia of Genes and Ge-
nomes pathways (Figure 5a, lower panel). In PICSAR knock-
down cSCC cells, significantly enriched gene ontology terms
included biological processes cell proliferation (P ¼ 5.5 
10e7), response to wounding (P¼ 4.0 10e6), and regulation
of cell migration (P ¼ 1.4  10e5). Molecular functions
significantly regulated included laminin binding (P ¼ 4.1 
10e4), extracellular matrix binding (P ¼ 9.0  10e4), and
peptidase regulator activity (P ¼ 1.1  10e3) (Figure 5a).
Significantly enriched Kyoto Encyclopedia of Genes and Ge-
nomes pathways included complement and coagulation cas-
cades (P¼ 6.6 10e3), hematopoietic cell lineage (P¼ 2.3
10e2), and extracellular matrix-receptor interaction (P¼ 2.4
10e2) (Figure 5a). These findings are consistent with functional
assays in culture showing decreased ERK1/2 phosphorylation,
cell proliferation, and cell migration after PICSAR knockdown
in cSCC cells. The top most upregulated and downregulated
genes (P < 0.05, FC log2 > 0.7) after PICSAR knockdown in
cSCC cells are shown in Figure 5b and Supplementary
Tables S1 and S2 online.
Regulation of mitogen-activated protein kinase phosphatases
by PICSAR
Among the top 50 most upregulated genes by knockdown of
PICSAR (P< 0.05) wasDUSP1 (dual-specificity phosphatase 1)
(Figure 5b, Supplementary Table S1). DUSP1 belongs to
the mitogen activated protein kinase phosphatase family and
it dephosphorylates p38, JNK, and ERK (Patterson et al.,
2009). Analysis of the mitogen activated protein kinase
phosphatase family in detail revealed upregulation of DUSP1
and DUSP6 (FC log2 ¼ 1.27 and 1.09, respectively) after
PICSAR knockdown (Figure 5c). As knockdown of PICSAR
had no effect on the activity on p38 or JNK, we focused on
DUSP6, a specific negative regulator of ERK2. Significant
upregulation of DUSP6 mRNA levels by PICSAR knockdown
in cSCC cells was verified by qRT-PCR (Figure 5d). Westernwww.jidonline.org 1703
Figure 2. PICSAR is specifically expressed by tumor cells in cSCC in vivo. (aed) Expression of PICSAR in paraffin-embedded tissue sections of AK (n ¼ 26),
cSCCIS (n ¼ 20), cSCC (n ¼ 21), and normal skin (n ¼ 9). PICSAR (red arrow) was analyzed with RNA-ISH. Specific signal for PICSAR was detected in tumor
cells in cSCC, cSCCIS, and AK, but not in epidermal keratinocytes in normal skin. Scale bar ¼ 20 mm. (e) Percentage of tissue sections with PICSAR positive
tumor cells in each group. *P < 0.05, Fisher’s exact test. AK, actinic keratosis; cSCC, cutaneous squamous cell carcinoma; cSCCIS, cSCC in situ; NS, normal
skin; PICSAR, P38 Inhibited Cutaneous Squamous cell carcinoma Associated lincRNA; RNA-ISH, RNA in situ hybridization.
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of DUSP6 at protein level after PICSAR knockdown
(Figure 5e, Supplementary Figure S6 online). Treatment
of cSCC cells with DUSP6 inhibitor (E)-2-benzylidene-3-
(cyclohexylamino)-2,3-dihydro-1H-inden-1-one increased
phosphorylation of ERK1/2 and potently abrogated a
decrease in ERK1/2 phoshorylation after PICSAR knockdown
providing further evidence for DUSP6 as the regulatory link
between PICSAR and ERK1/2 (Figure 5f).Journal of Investigative Dermatology (2016), Volume 136Knockdown of PICSAR suppresses growth of cSCC
xenografts in vivo
The role of PICSAR in cSCC progression in vivo was investi-
gated using a cSCC xenograft model in severe combined
immunodeficient mice. UT-SCC12A cells were transfected
with PICSAR siRNA1 and control siRNA, and incubated for 72
hours. Transfected cells were injected subcutaneously into the
backof the severe combined immunodeficientmice and tumor
growth was measured twice a week. Knockdown of PICSAR
Figure 3. Expression of PICSAR is downregulated by p38 MAPK pathway. (a) Upper panel: UT-SCC12A cells were treated for 24 hours with MEK1/2 inhibitor
(PD98059, 30 mM) and p38 inhibitors specific for p38a/b (SB203580, 10 mM) or all p38 isoforms (p38a/b/g/d) (BIRB796, 10 mM). Expression of PICSAR was
measured by qRT-PCR and corrected for the levels of b-actin mRNA in the same samples (mean  SD; control n ¼ 2, BIRB n ¼ 4, PD n ¼ 4, SB n ¼ 2). Lower
panel: levels of phosphorylated CREB (p-CREB), a downstream mediator of the p38 MAPK pathway, and ERK1/2 (p-ERK1/2) were determined by western blot
analysis of the corresponding cell lysates to verify the effect of p38 and MEK1/2 inhibitors. (b) Upper panel: UT-SCC12A cells were transfected with negative
control siRNA, and with p38a or p38d siRNA alone or in combination (p38a/d) (75 nM). Expression of PICSAR was determined with qRT-PCR 72 hours after
transfection (mean  SD; n ¼ 3). Lower panel: Cell lysates were analyzed for p38a and p38d protein levels by western blotting. Levels of p38a and p38d
quantitated densitometrically and corrected for b-actin levels in the same samples are shown below the western blots relative to levels in untreated control cells
(1.0). (c) UT-SCC12A cells were infected with control adenovirus (RAdLacZ) and with adenovirus containing the dominant negative MKK3b (RAdMKK3bA).
PICSAR expression was determined by qRT-PCR 24, 48, and 72 hours after infection (mean  SD; n ¼ 3). *P < 0.05, **P < 0.01, ***P < 0.001; Student’s t-test.
CREB, CRE-binding protein; ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; MEK, MAPK/ERK kinase; MKK3b, MAP kinase
kinase 3b; PICSAR, P38 Inhibited Cutaneous Squamous cell carcinoma Associated lincRNA; qRT-PCR, quantitative real-time reverse transcriptase-PCR.
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tumors compared with the control tumors noted already at 4
days (Figure 6a). Tumors were harvested 18 days after im-
plantation and weighed. The mass of PICSAR knockdown tu-
mors was significantly lower compared with the control
tumors (Figure 6b). Extended incubation of PICSAR siRNAtransfected UT-SCC12A cells showed that the expression of
PICSAR was still reduced by 55% after 14 days (data not
shown). The relative number of proliferating (Ki-67 positive)
tumor cells was significantly lower in xenografts established
with cSCC cells transfected with PICSAR siRNA, as compared
with the control siRNA tumors (Figure 6c and d).www.jidonline.org 1705
Figure 4. Knockdown of PICSAR inhibits proliferation and migration of cSCC cells. (a) Upper panel: cSCC cells were transfected with negative control siRNA
or PICSAR siRNA1 (75 nM). PICSAR expression was determined 72 hours after transfection by qRT-PCR and corrected for b-actin mRNA levels in the same
samples (mean  SD; n ¼ 3). Lower panel: expression of PICSAR in cSCC cells was determined with RNA-ISH after transfection with negative control siRNA or
PICSAR siRNA1. Scale bar¼ 10 mm. (b) The number of viable cSCC cells (UT-SCC118) was determined with WST-1 assay 48 and 72 hours after transfection with
PICSAR and control siRNA1 (75 nM) (n ¼ 3e8). (c) Cell lysates of cSCC cells (UT-SCC12A and UT-SCC118) were analyzed by western blotting for the levels of
phosphorylated ERK1/2 (p-ERK1/2) and Ki-67 proliferation marker 72 hours after transfection with PICSAR siRNA1 and control siRNA. Levels of p-ERK1/2 and
Ki-67 quantitated densitometrically and corrected for total ERK1/2 and b-actin levels, respectively, in the same samples are shown below the western blots
relative to levels in untreated control cells (1.0). (d) cSCC cells (UT-SCC12A) were transfected with PICSAR siRNA1 or control siRNA (75 nM both). Forty-eight
hours after transfection, cells were incubated for 6 hours with hydroxyurea (1 mM) to prevent cell proliferation. Cell monolayer was scratched with a sterile
pipette tip and incubation was continued in DMEM and 1% fetal calf serum with 0.5 mM hydroxyurea. Photomicrographs were taken at 0, 16, and 24 hours
from three parallel wells (3e5 images per well). (e) Quantitation of the relative cell migration rates (n ¼ 3e5). Mean  SD is shown; *P < 0.05, **P < 0.01,
***P < 0.001; Student’s t-test. cSCC, cutaneous squamous cell carcinoma; ERK, extracellular signal-regulated kinase; Ki-67, marker of proliferation Ki-67;
PICSAR, P38 Inhibited Cutaneous Squamous cell carcinoma Associated lincRNA; qRT-PCR, quantitative real-time reverse transcriptase-PCR; RNA-ISH, RNA in
situ hybridization; WST, water-soluble tetrazolium salt.
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More than 18,000 annotated lncRNA transcripts have been
identified in the human genome, but the function of most
lncRNAs is still unknown. Dysregulation of specific lncRNAs
has been documented in different cancer types and they have
been proposed as biomarkers and therapeutic targets in
cancer (Serviss et al., 2014; Wahlestedt, 2013; Yang et al.,
2014). For example, a widely characterized lncRNA,
HOTAIR has been suggested as a prognostic marker in
different cancers (Yao et al., 2014). Several lncRNAs with
oncogenic functions have been characterized, such as
HOTAIR, MALAT1, and ANRIL (Geisler and Coller, 2013;
Rinn and Chang, 2012). On the other hand, certain
lncRNAs have been shown to possess tumor suppressive
functions, adding to the complexity of the role of lncRNAs
in cancer progression (Huarte et al., 2010; Mourtada-
Maarabouni et al., 2009).
Here, we have characterized the role of lincRNA PICSAR
(LINC00162) in the progression of cSCC, the most common
metastatic skin cancer (Madan et al., 2010; Ratushny et al.,Journal of Investigative Dermatology (2016), Volume 1362012). The whole transcriptome expression analysis identi-
fied PICSAR as one of the differentially expressed lncRNAs
with the highest mean expression level in cSCC cells
compared with NHEKs. Overexpression of PICSAR was noted
in primary and metastatic cSCC cell lines compared with
NHEKs using RNA-seq analysis, qRT-PCR, and RNA-ISH.
Moreover, analysis of PICSAR levels by qRT-PCR revealed
overexpression of PICSAR in cSCC tumors in vivo, as
compared with normal skin. In addition, RNA-ISH analysis of
a panel of tissue samples from normal skin, premalignant
lesions (AKs), and cSCCs revealed tumor cell-associated
labeling for PICSAR in cSCCs, but not in normal skin.
These results show that the expression of PICSAR is specif-
ically induced in tumor cells in cSCCs, suggesting PICSAR as
a biomarker for cSCC. Furthermore, expression of PICSAR in
a subset of AKs and cSCCIS provides evidence that the
induction of PICSAR expression is an early event in kerati-
nocyte carcinogenesis and may play a role in the progression
of AKs to cSCCIS and eventually to invasive cSCC. However,
it is evident that further analysis of a larger panel of cSCCs
Figure 5. Alteration of gene expression profile in cSCC cells after knockdown of PICSAR. (aec) Three cSCC cell lines (UT-SCC12A,UT-SCC59A, andUT-SCC118)
were transfected with PICSAR siRNA1 or control siRNA. Seventy-two hours after transfection, whole transcriptome analysis was performed with RNA-seq. The
results were examined as log2 fold change (FC) values between the mean expression values of two sample groups. (a) Summary of ingenuity pathway analysis (IPA)
biofunctions (upper panel), gene ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways (lower panel) related to PICSAR
knockdown (P < 0.05, FC log2 > 0.7). GO and KEGG results shown are average P-values of three cSCC cell lines (P < 0.05). (b) Heatmap showing the 50 most
upregulated and downregulated genes after PICSAR knockdown (P < 0.05, FC log2 > 0.7). (c) Heatmap showing mitogen-activated protein kinase phosphatases
regulated by knockdownof PICSAR in cSCC cells. (d) Expression ofDUSP6mRNAwas determined by qRT-PCR in cSCC cells 72 hours after PICSAR knockdown. b-
ActinmRNA levelswere determined as a reference gene. (e)DUSP6protein levelswere determined bywestern blotting analysis in cSCC cells 72 hours after PICSAR
knockdown. Levels of DUSP6 quantitated densitometrically and corrected for b-actin levels in the same samples are shown below the western blots relative to the
levels in control cells (1.0). (f)DUSP6 inhibitor BCIwas added to cSCCcells 24 hours after PICSAR knockdownand incubationwas continued for 24 hours. Levels of
phosphorylated and total ERK1/2were determined bywestern blot analysis. Levels of p-ERK1/2 quantitated densitometrically and corrected for ERK1/2 levels in the
same samples are shown below the western blots relative to the levels in control cells (1.0). *P < 0.05, **P < 0.01; Student’s t-test. BCI, (E)-2-benzylidene-3-
(cyclohexylamino)-2,3-dihydro-1H-inden-1-one; cSCC, cutaneous squamous cell carcinoma; DUSP6, dual specificity phosphatase 6; ERK, extracellular signal-
regulated kinase; PICSAR, P38 Inhibited Cutaneous Squamous cell carcinoma Associated lincRNA; qRT-PCR, quantitative real-time reverse transcriptase-PCR.
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parameters is required to fully evaluate the role of PICSAR as
a biomarker for cSCC progression.
Solar UV-radiation is the most common environmental
carcinogen causing skin cancer (Kivisaari and Ka¨ha¨ri, 2013;
Ratushny et al., 2012). There is evidence that UVA activatesERK1/2 signaling and proliferation in keratinocytes, and may
in this way promote cutaneous carcinogenesis (Bachelor and
Bowden, 2004; He et al., 2004). Activation of MAPK
signaling is associated with cSCC progression and basal
activation of ERK1/2 is detected in tumor cells in cSCC
(Kivisaari et al., 2010; Lambert et al., 2014; Toriseva et al.,www.jidonline.org 1707
Figure 6. Knockdown of PICSAR suppresses growth of cSCC xenografts. (a) UT-SCC12A cells were transfected with PICSAR targeted siRNA1 or negative
control siRNA. Seventy-two hours after transfection, cells (7  106) were injected subcutaneously into the back of SCID mice and the growth of tumors
was measured twice a week (n ¼ 7 in both groups). (b) Xenografts were harvested 18 days after inoculation and weighed. Mean  SEM is shown; *P < 0.05,
**P < 0.01, ***P < 0.001; Student’s t-test. (c) Histology of the tumors was analyzed in hematoxylin and eosin (H&E) stained tumor sections. Ki-67 was detected
in xenografts by immunohistochemistry. Hematoxylin was used as a counterstain. Scale bar ¼ 100 mm. (d) The relative number of Ki-67 positive cells was
determined by counting 500e2600 cells in all tumor sections (n ¼ 7 in both groups) at 20 magnification. *P < 0.05, Mann-Whitney U-test. cSCC, cutaneous
squamous cell carcinoma; Ki-67, marker of proliferation Ki-67; PICSAR, P38 Inhibited Cutaneous Squamous cell carcinoma Associated lincRNA; SCID, severe
combined immunodeficient; SEM, standard error of mean.
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17082012). Moreover, activation of p38 MAPK pathway, espe-
cially p38a and p38d, plays a role in invasion of cSCC cells
and growth of cSCC in vivo (Junttila et al., 2007; Schindler
et al., 2009). It has been shown that cSCC cells predomi-
nantly express p38a and p38dMAPK isoforms and that p38 is
activated in cSCC cells at basal level (Junttila et al., 2007). In
this context, we examined the role of MAPK signaling in the
regulation of PICSAR expression. Inhibition of the activity of
p38a and p38d with BIRB796 or with specific siRNAs
resulted in upregulation of PICSAR expression. Inhibition of
ERK1/2 activation with MEK1/2 inhibitor PD98059 had no
effect on PICSAR expression. These results identify PICSAR as
a target for p38 signaling pathway in cSCC cells.
Knockdown of PICSAR expression in cSCC cells resulted in
significant inhibition in the growth of cSCC xenograft tumors
already at the early stage compared with control siRNA group.
These results provide evidence that PICSAR plays a role in
implantation and early growth of cSCC tumor cells in vivo.
Functional studies with cSCC cells indicated that knockdown
of PICSAR expression suppressed cellular functions important
in cancer progression, that is, proliferation and migration of
cSCC cells. Moreover, knockdown of PICSAR significantly
decreased the levels of p-ERK1/2, suggesting that the func-
tional effect of PICSAR involves regulation of ERK1/2 pathway.Journal of Investigative Dermatology (2016), Volume 136The molecular background for the role of PICSAR in cSCC
growth and migration was examined by RNA-seq analysis of
three distinct cSCC cell lines after PICSAR knockdown.
Pathway analysis of the gene expression profile of cSCC cells
revealed that significantly downregulated genes after PICSAR
knockdown were associated with biofunctions M-phase
of tumor cell lines, transformation of tumor cell lines,
transformation of epithelial cell lines, and phosphorylation of
L-serine. In addition, differentially expressed genes were
associated with significantly enriched gene ontology terms
cell proliferation, regulation of cell migration, and extracel-
lular matrix binding. Among the genes most upregulated
by PICSAR knockdown was DUSP1, which codes for
dual specificity phosphatase 1 (Patterson et al., 2009). As
decreased activation of ERK1/2 was noted after PICSAR
knockdown, we wanted to examine the role of dual specificity
phosphatases in detail. Further analysis revealed upregulation
of DUSP6, a specific ERK2 phosphatase at mRNA and protein
level in cSCC cells after PICSAR knockdown. In addition, in
the presence of DUSP6 inhibitor, PICSAR knockdown had no
effect on ERK1/2 activation providing further evidence for
DUSP6 as regulatory link between PICSAR and ERK1/2
signaling pathway. Expression of DUSP6 in cSCC cells has
previously been shown to be upregulated by keratinocyte
M Piipponen et al.
PICSAR Promotes Growth of Squamous Cell Carcinomagrowth factor (KGF), which suppresses the malignant pheno-
type of these cells (Toriseva et al., 2012). However, keratino-
cyte growth factor had no effect on the expression of PICSAR
in cSCC cells (data not shown). DUSP6 is activated on binding
to ERK2 and it specifically dephosphorylates and inactivates
ERK2, but not JNK or p38 (Groom et al., 1996; Muda et al.,
1998). This is in accordance with our finding that ERK1/2
activity is decreased after PICSAR knockdown but not the
levels of active JNK and p38. LncRNAs can regulate gene
expression both at transcriptional and posttranscriptional
level (Geisler and Coller, 2013). RNA-seq analysis of cSCC
cells after PICSAR knockdown revealed significantly altered
expression of numerous protein and nonprotein coding genes,
which could mediate the effects of PICSAR. The cytoplasmic
localization of PICSAR in cSCC cells suggests that it may
regulate the stability of DUSP6 mRNA directly or indirectly.
Nevertheless, these findings provide evidence that PICSAR
knockdown decreases ERK1/2 activation in cSCC cells, which
in turn may lead to decreased cell proliferation, viability, and
migration. These observations also identify PICSAR as a reg-
ulatory link between p38 and ERK1/2 signaling pathways.
At present, there is little information available on the
expression of PICSAR in human tissues outside central ner-
vous system (Kawashima et al., 2006; Mills et al., 2013). The
gene coding for PICSAR is located in 21q22.3, between
protein coding genes ADARB1 (adenosine deaminase, RNA-
specific, B1) and FAM207A (family with sequence similarity
207, member A). Interestingly, single nucleotide poly-
morphisms, copy-number alterations, and loss of heterozy-
gosity in 21q22.3 associated with certain cancers have been
found by genome-wide association studies (Boyd et al., 2012;
Hwang et al., 2008; Ve´kony et al., 2007; Wu et al., 2011). It
remains to be elucidated whether any of these genomic
alterations involve PICSAR gene.
In summary, we have identified PICSAR as a lincRNA
specifically overexpressed in cSCC cells in culture and
in vivo. In addition, we show that PICSAR regulates prolif-
eration and migration of cSCC cells and growth of cSCCs
in vivo. Our results also provide mechanistic evidence that
PICSAR increases activity of ERK1/2 pathway via inhibition of
MAPK phosphatase DUSP6. The results of this study impli-
cate PICSAR in cSCC progression, and identify this lincRNA
as a biomarker and putative therapeutic target in cSCC.
MATERIALS AND METHODS
Ethical issues
The use of tumor and normal skin samples was approved by the Ethics
Committee of the Hospital District of Southwest Finland. All partici-
pants gave their written informed consent and the study was carried
out with the permission of Turku University Hospital, according to the
Declaration of Helsinki. The experiments with mice were performed
with the permission of the State Provincial Office of Southern Finland.
Tissue samples
Tissue samples of cSCC tumors (n ¼ 6) and normal skin (n ¼ 7) were
collected in Turku University Hospital (Riihila¨ et al., 2014). Tissue
microarrays consisting of samples from normal sun-protected skin
(n ¼ 9), AK (n ¼ 26), cSCCIS (n ¼ 20), and cSCC (n ¼ 21) were
generated from the archival paraffin blocks from the Department of
Pathology, Turku University Hospital (Farshchian et al., 2015; Riihila¨et al., 2015). Formalin-fixed paraffin-embedded xenograft tumors
were established with human UT-SCC12A cell line in severe com-
bined immunodeficient mice.
Cell cultures
cSCC cell lines were established from surgically removed SCCs of the
skin in Turku University Hospital (Lansdorf et al.,1999; Stokes et al.,
2010). The authenticity of all cSCC cell lines has been verified by
short tandem repeat profiling (DDC Medical, Fairfield, OH). NHEKs
were established from skin of healthy individuals undergoing mam-
moplasty (Farshchian et al., 2011) and NHEK-PC was purchased from
PromoCell (Heidelberg, Germany). cSCC cells and NHEKs were
cultured as previously described (Farshchian et al., 2015; Riihila¨ et al.,
2015). For inhibition of MAPKs, cSCC cells were treated for 24 hours
with p38 inhibitors BIRB796 and SB203580 (10 mMeach), andMEK1/
2 inhibitor PD98059 (30 mM) (all from Calbiochem, La Jolla, CA). For
inhibition of DUSP6, 24 hours after PICSAR knockdown, cSCC cells
were treated with 5 mM (E)-2-benzylidene-3-(cyclohexylamino)-2,3-
dihydro-1H-inden-1-one (Calbiochem, San Diego, CA) for 6 hours
and incubation was continued for 18 hours with 1 mM (E)-2-
benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one.
RNA analysis and RNA in situ hybridization
Protocols for RNA sequencing analysis, quantitative real-time PCR,
and RNA-ISH are provided in Supplementary Materials and Methods
online.
Knockdown of PICSAR and functional studies
Protocols for siRNA transfection, adenoviral gene delivery, and
assays for cell proliferation, migration and western blotting are
provided in Supplementary Materials and Methods.
Human cSCC xenografts
Protocols for establishing human cSCC xenografts and tumor
immunohistochemistry are provided in Supplementary Materials and
Methods.
Statistical analysis
Statistical analyses were performed using SPSS Statistics for
Windows, v. 20.0 (IBM, Armonk, NY). Student’s t-test and Mann-
Whitney U-test were used to compare the means between two
groups. Statistical analysis for immunohistochemistry stainings was
performed with Fisher’s exact test.
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